| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Global PERFORMA Phase 3 trial in MASH progressing as planned |
| 29 Oct 2026 |
8-K: Creation of a Direct Financial Obligation
On October 27, 2026, Altimmune, Inc. (the “Company”), has drawn $10.0 million in an aggregate principal amount (“Tranche Three”) from its $125.0 million Loan and Security Agreement, dated as of May 13, 2025 (as amended by the Amendment t... |
| 27 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution |
| 29 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 24, 2026, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) appointed Richard Menziuso as the Company’s Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2... |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Reported positive topline data from RECLAIM Phase 2 trial in AUD |
| 28 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial |
| 16 Jun 2026 |
8-K: Other Events
On June 16, 2026, Altimmune, Inc. (the “Company”) announced plans to relocate its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey later this year. The new headquarters is in a geography with a strong presence... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 |
| 24 Apr 2026 |
8-K: Entry into a Material Definitive Agreement
64,250,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) PRE-FUNDED WARRANTS TO PURCHASE 10,750,000 SHARES OF COMMON STOCK WARRANTS TO PURCHASE 75,000,000 SHARES OF COMMON STOCK (OR PRE- FUNDED WARRANTS IN LIEU THEREOF) |
| 16 Apr 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
The undersigned, being the Chief Executive Officer of Altimmune, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby amend and certify as follows: |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
Pemvidutide granted FDA Breakthrough Therapy Designation in MASH |
| 03 Feb 2026 |
8-K: Other Events
Altimmune, Inc. (the "Company") has established Thursday, April 16, 2026 as the date of the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") to align with the standard second quarter annual meeting calendar for c... |
| 28 Jan 2026 |
8-K: Entry into a Material Definitive Agreement
This Securities Purchase Agreement (this “Agreement”) is dated as of January 27, 2026, between Altimmune, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its succ... |
| 19 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
48 - Week IMPACT Phase 2b Topline Data Presentation December 2025 |
| 01 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of November 30, 2025, by and between Jerry Durso (“Executive”) and Altimmune, Inc., a Delaware corporation (“Altimmune” or the “Company”). |
| 06 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
As further set forth in this agreement (this “Agreement”), Altimmune, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Leerink Partners LLC (the “Agent”) as sales agent, the Company’s com... |
| 06 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
This AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (this “Amendment”), is dated as of November 5, 2025 (the “First Amendment Effective Date”) and is entered into by and among ALTIMMUNE, INC., a Delaware corporation (“Company”), ALTIMMUN... |
| 03 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
As previously disclosed on February 24, 2025, Altimmune, Inc.’s (the “Company’s”) former Chief Medical Officer, Dr. Scott Harris, provided the Company advance notice of his intention to retire from Altimmune as of February 28, 2026 (the ... |
| 25 Sep 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On September 25, 2025, Altimmune, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). As of August 12, 2025, the record date for the 2025 Annual Meeting, there were 88,257,253 shares of the Comp... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy |
Loading...